Stockscreener 앱 받기
12.86
2.06%
-0.27
시간 외 거래:
12.97
0.11
+0.86%
전일 마감가:
$13.13
열려 있는:
$12.99
하루 거래량:
956.96K
Relative Volume:
0.58
시가총액:
$984.03M
수익:
$31,000
순이익/손실:
$-54.42M
주가수익비율:
-13.15
EPS:
-0.9778
순현금흐름:
$-48.99M
1주 성능:
+5.76%
1개월 성능:
+34.52%
6개월 성능:
+152.65%
1년 성능:
+116.13%
1일 변동 폭
$12.40
$12.99
1주일 범위
$11.77
$13.82
52주 변동 폭
$4.35
$13.82
Candel Therapeutics Inc Stock (CADL) Company Profile
명칭
Candel Therapeutics Inc
전화
617-916-5445
주소
117 KENDRICK STREET, NEEDHAM
Compare CADL vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
12.86 | 945.00M | 31,000 | -54.42M | -48.99M | -0.9778 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-10-28 | 개시 | Stephens | Overweight |
| 2025-09-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-06-30 | 재개 | H.C. Wainwright | Buy |
| 2025-02-20 | 개시 | Citigroup | Buy |
| 2025-02-19 | 개시 | Canaccord Genuity | Buy |
| 2025-02-07 | 개시 | BofA Securities | Buy |
| 2022-12-02 | 개시 | H.C. Wainwright | Buy |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-08-23 | 개시 | Credit Suisse | Outperform |
| 2021-08-23 | 개시 | Jefferies | Buy |
| 2021-08-23 | 개시 | UBS | Buy |
모두보기
Candel Therapeutics Inc 주식(CADL)의 최신 뉴스
Candel Therapeutics (CADL) Is Up 5.4% After Steep Q2 Loss Widening Has The Bull Case Changed? - Yahoo Finance
Analysts Issue Forecasts for CADL FY2026 Earnings - MarketBeat
Candel Therapeutics, Inc. (CADL) Stock Price, News, Quote & History - Yahoo Finance
Candel Therapeutics (CADL) Faces Bigger Losses As Its Valuation Still Looks Pricey - Yahoo Finance
CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally? - Stocktwits
Candel Therapeutics (CADL) Is Up 26.4% After Swinging Back to Losses in Q2 2026 – Has The Bull Case Changed? - simplywall.st
Candel Therapeutics (NASDAQ:CADL) CTO Seshu Tyagarajan Sells 7,000 Shares of Stock - MarketBeat
Candel Therapeutics (CADL) CTO sells 7,000 shares via 10b5-1 plan - Stock Titan
Candel Therapeutics (NASDAQ:CADL) Hits New 1-Year HighHere's Why - MarketBeat
CADL Stock Edges Up After Hours On Strong Extended Prostate Cancer Data - Stocktwits
Candel Therapeutics (NASDAQ: CADL) insider plans 7,000-share 10b5-1 sale - Stock Titan
Candel Therapeutics (NASDAQ:CADL) Trading 6.4% Higher Following Analyst Upgrade - MarketBeat
Freedom Broker raises Candel Therapeutics stock price target on trial progress - Investing.com Canada
Weekly Recap: CAN-2409 BLA filing, 2027 U.S. launch target and Q2 widened loss, shares up - TradingView
Research Analysts Set Expectations for CADL Q3 Earnings - MarketBeat
CADL Q3 EPS Estimate Reduced by Brookline Capital Markets - MarketBeat
Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow - Stocktwits
This Small-Cap Biotech Is Having Its Best Week In A Month – Here’s What’s Driving It - Stocktwits
(CADL) Risk Channels and Responsive Allocation - Stock Traders Daily
Candel Therapeutics (NASDAQ:CADL) Lowered to Sell Rating by Wall Street Zen - MarketBeat
A Quick Look at Today's Ratings for Candel Therapeutics(CADL.US), With a Forecast Between $12 to $23 - Moomoo
Stifel Nicolaus Remains a Buy on Candel Therapeutics (CADL) - The Globe and Mail
Candel Therapeutics (CADL) Receives a Hold from Bank of America Securities - The Globe and Mail
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Candel Therapeutics (NASDAQ:CADL) Stock Price Expected to Rise, Bank of America Analyst Says - MarketBeat
LifeSci Capital Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Candel Therapeutics (NASDAQ:CADL) Stock Price Down 4.6% After Earnings Miss - MarketBeat
Candel Therapeutics, Inc. Stock 12‑Month Price Target Raised to $20.88, Implies 77% Upside - TradingView
BofA Adjusts Price Target on Candel Therapeutics to $12 From $9 - Moomoo
Equities Analysts Offer Predictions for CADL FY2028 Earnings - MarketBeat
A Quick Look at Today's Ratings for Candel Therapeutics(CADL.US), With a Forecast Between $12 to $25 - Moomoo
Biotech Stocks At 52-Week HighsPARK +10%, AVAH +24%, CADL +10% On Q2 Reports, LH, COAG - RTTNews
Candel Therapeutics (NASDAQ:CADL) Releases Earnings Results, Misses Expectations By $0.30 EPS - MarketBeat
CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4 - TradingView
Candel Therapeutics (NASDAQ:CADL) Sets New 12-Month HighHere's What Happened - MarketBeat
HC Wainwright Reaffirms Buy Rating for Candel Therapeutics (NASDAQ:CADL) - MarketBeat
Candel Therapeutics Q2 EPS of $(0.52) misses estimates - scanx.trade
Candel Therapeutics Reports Q2 2026 Financials and Pipeline Progress in SEC Form 10-Q - Kalkine Media
Candel Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Candel Therapeutics Inc For: 13 August By Investing.com - Investing.com Canada
Candel Therapeutics Q2 Loss Widens - marketscreener.com
Earnings Flash (CADL) Candel Therapeutics Posts Q2 Net Loss $0.52 a Share, vs. FactSet Est of $0.21 Loss - marketscreener.com
Candel Therapeutics, Inc. Q2 2026: Net income $(38.9M), EPS $(0.52) — 10-Q Summary - TradingView
Candel Therapeutics (NASDAQ: CADL) widens H1 2026 loss while boosting cash above $200M - Stock Titan
Candel Therapeutics reports Q2 2026 net loss $38.9M, cash $201.6M; plans BLA submission Q4 2026 - TradingView
Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - The Manila Times
Candel's Prostate Therapy Candidate Shows 39% Disease-Free Survival Improvement - Stock Titan
Candel Therapeutics Q2 FY26 net loss widens to $38.9 million; R&D expense more than doubles to $19.8 million - Bitget
Candel Therapeutics at canaccord growth conference: prostate cancer push By Investing.com - Investing.com Canada
Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up - MarketBeat
Candel Therapeutics at canaccord growth conference: prostate cancer push - Investing.com
Candel Therapeutics Inc (CADL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
3.22%
자본화:
|
볼륨(24시간):